Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.
about
Applications of next-generation sequencing to blood and marrow transplantationGenetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphomaSystematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in miceTumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regionsControl of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells.Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphomaBiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.Therapeutic vaccine for lymphoma.Profound impairment of adaptive immune responses by alkylating chemotherapyDeveloping idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.Adoptive T-cell therapy for B-cell malignancies.Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.Vaccination with immunoglobulin frame region-derived nonapeptide elicits cellular immune response against lymphoma in human leukocyte antigen-A2.1 transgenic mice.The promise of the anti-idiotype concept.A simple, clinically relevant therapeutic vaccine shows long-term protection in an aggressive, delayed-treatment B lymphoma model.Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides
P2860
Q26852890-E6B12387-7936-43D4-B3F8-F0FF86832E37Q33814247-69227154-6559-45AD-A6DE-3DE3C32ECD08Q33917224-5E40F4F5-C4F7-4550-8CAA-EEC851A846F4Q33989839-2D1A8F2C-4812-4CC1-A6E4-04D4812EFD91Q34097414-F3C3B01B-84B6-482A-AA05-5FF1A4F4420CQ34110768-B8C256B0-DD0F-4890-8B7E-509AA6F35964Q34534544-3C1C5F7E-2429-4F68-BA4D-5B6B26865577Q35113388-66BF9DE6-B5BD-4753-87C0-0A4CFC2F599AQ35114545-259E64A1-9B56-4AF0-BAAA-0EC1D62DAAF5Q36675461-EDF83F17-14B3-403F-9EE8-FA55960910C1Q36746586-B2AA2360-D808-420D-9806-31B3F196F97EQ36922577-F5FD9289-A432-4013-983F-F46317A8B216Q37142202-420D1CEA-AC06-43B8-A395-C09AFFD3DB7EQ37447307-912F7439-9E14-4720-8169-60776142CA6FQ37505384-EE478474-2C29-4ABE-8754-B38D0A5ABFB4Q37810116-72668070-3DDD-4493-9E33-19AE656B455AQ38286381-1E06E595-A4AF-40CA-9061-4BCBB021986EQ38532002-FF81FECB-1F21-4841-BF10-5FD0D8D053D3Q39527856-6CFC7228-ABB7-4DB4-B98D-208BB30794ACQ42419120-B6F77702-5AC8-4501-B396-367E95960749Q47357871-90F78063-B613-4C29-B778-B23638093A97Q56994227-037159F2-F25E-40E5-9E74-F043D9104D6F
P2860
Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Autologous lymphoma vaccines i ...... nst multiple, unique epitopes.
@ast
Autologous lymphoma vaccines i ...... nst multiple, unique epitopes.
@en
type
label
Autologous lymphoma vaccines i ...... nst multiple, unique epitopes.
@ast
Autologous lymphoma vaccines i ...... nst multiple, unique epitopes.
@en
prefLabel
Autologous lymphoma vaccines i ...... nst multiple, unique epitopes.
@ast
Autologous lymphoma vaccines i ...... nst multiple, unique epitopes.
@en
P2093
P2860
P356
P1476
Autologous lymphoma vaccines i ...... nst multiple, unique epitopes.
@en
P2093
Carol B Kobrin
Larry W Kwak
Sivasubramanian Baskar
P2860
P304
P356
10.1172/JCI20312
P407
P577
2004-05-01T00:00:00Z